Table 1.
Characteristics of included randomized controlled trials studies
|
Study (First author) |
Reported date |
Study location |
Total sample size |
Mean age (range), years |
Sex/male (%) |
Type of infection |
Interventions |
|---|---|---|---|---|---|---|---|
|
Rex et al. [15] |
1994 |
America |
206 |
59 (na) |
105 (56.0) |
candidemia |
FLU/AMP |
|
Mora-Duate et al. [16] |
2002 |
America |
224 |
56 (18–84) |
125 (55.8) |
invasive candidiasis |
CAS/AMP |
|
Colombo et al. [17] |
2003 |
America/Europe/Asia |
210 |
52.7 (18–97) |
120 (57.1) |
invasive candidiasis |
CAS/AMP |
|
Pappas et al. [18] |
2007 |
America/Europe/Asia |
578 |
55.8 (24–92) |
336 (58.1) |
candidemia or invasive candidiasis |
MIC/CAS |
|
Reboli et al. [19] |
2007 |
America |
245 |
58.1 (24–91) |
125 (51.0) |
invasive candidiasis |
AND/FLU |
|
Kuse et al. [20] |
2007 |
America/Europe/Asia/Africa |
531 |
55.3 (18–84) |
325 (61.2) |
candidemia or invasive candidiasis |
MIC/AMP |
|
Kullberg et al. [21] |
2019 |
Europe |
440 |
57.9 (na) |
269 (61.1) |
candidemia or invasive candidiasis |
CAS/ISA |
FLU, Fluconazole; AMP, Amphotericin B; VOR, Voriconazole; CAS, Caspofungin; AND, Anidulafungin; MIC, micafungin; na, data not available.